<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03896009</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-07-301</org_study_id>
    <nct_id>NCT03896009</nct_id>
  </id_info>
  <brief_title>Maximizing Outcomes in Treating Acute Migraine</brief_title>
  <acronym>MOMENTUM</acronym>
  <official_title>MOMENTUM: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan,
      which is being developed for the acute treatment of migraine with or without aura in adults.
      AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This
      study is designed to evaluate the efficacy and safety of AXS-07 compared to meloxicam,
      rizatriptan, and placebo for the treatment of a migraine attack.

      This is a randomized, double-blind, 4-arm, parallel group, single-dose, placebo-controlled
      trial. Subjects who successfully complete screening and continue to meet all entry criteria
      will be randomly assigned to take one dose of either AXS-07, meloxicam, rizatriptan, or
      placebo upon the occurrence of a qualifying migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Actual">December 10, 2019</completion_date>
  <primary_completion_date type="Actual">December 10, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects reporting headache pain freedom</measure>
    <time_frame>Hour 2 following dose administration</time_frame>
    <description>Absence of headache pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with absence of Most Bothersome Symptom</measure>
    <time_frame>Hour 2 following dose administration</time_frame>
    <description>Absence of most bothersome symptom, defined at the onset of migraine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects reporting sustained headache pain freedom</measure>
    <time_frame>Hours 2 through 24 following dose administration</time_frame>
    <description>Sustained headache pain freedom without use of rescue medication and no relapse of headache pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects reporting headache pain relief</measure>
    <time_frame>Hour 2 following dose administration</time_frame>
    <description>Mild or no headache pain</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1594</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>AXS-07</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taken once upon a qualifying migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taken once upon a qualifying migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rizatriptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taken once upon a qualifying migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taken once upon a qualifying migraine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-07 (MoSEIC meloxicam and rizatriptan)</intervention_name>
    <description>AXS-07 taken once upon onset of a qualifying migraine.</description>
    <arm_group_label>AXS-07</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>Meloxicam taken once upon onset of a qualifying migraine.</description>
    <arm_group_label>Meloxicam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rizatriptan</intervention_name>
    <description>Rizatriptan taken once upon onset of a qualifying migraine.</description>
    <arm_group_label>Rizatriptan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken once upon onset of a qualifying migraine.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Has an established diagnosis of migraine with or without aura.

          -  Has experienced an inadequate response to prior acute treatments.

        Key Exclusion Criteria:

          -  Has previously received any investigational drug or device or investigational therapy
             within 30 days before Screening.

          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MOMENTUM Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>AXS-07</keyword>
  <keyword>Meloxicam</keyword>
  <keyword>Rizatriptan</keyword>
  <keyword>Axsome</keyword>
  <keyword>Axsome Therapeutics</keyword>
  <keyword>MoSEIC meloxicam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

